These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10966008)

  • 1. Clinical experience in coronary bypass surgery for abciximab-treated patients.
    Lemmer JH
    Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S33-7. PubMed ID: 10966008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery.
    Kereiakes DJ
    Am J Cardiol; 1998 Feb; 81(3):373. PubMed ID: 9468091
    [No Abstract]   [Full Text] [Related]  

  • 3. Coronary artery bypass graft in abciximab-treated patients.
    LeNarz LA
    Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S38-42. PubMed ID: 10966009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abciximab (ReoPro) removal during cardiopulmonary bypass with a hemoconcentrator.
    Steinhubl SR; Moore SA; Lincoff AM
    J Thorac Cardiovasc Surg; 2000 Feb; 119(2):401-2. PubMed ID: 10649221
    [No Abstract]   [Full Text] [Related]  

  • 5. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab.
    Juergens CP; Yeung AC; Oesterle SN
    Am J Cardiol; 1997 Jul; 80(1):74-5. PubMed ID: 9205024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of cardiac surgery in the abciximab-treated patient.
    Silvestry SC; Smith PK
    Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S12-9. PubMed ID: 10966006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.
    Lincoff AM; LeNarz LA; Despotis GJ; Smith PK; Booth JE; Raymond RE; Sapp SK; Cabot CF; Tcheng JE; Califf RM; Effron MB; Topol EJ
    Ann Thorac Surg; 2000 Aug; 70(2):516-26. PubMed ID: 10969673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of abciximab for treatment of early coronary artery stent thrombosis.
    Casserly IP; Hasdai D; Berger PB; Holmes DR; Schwartz RS; Bell MR
    Am J Cardiol; 1998 Oct; 82(8):981-5. PubMed ID: 9794358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergency coronary artery bypass graft surgery in abciximab-treated patients.
    Lemmer JH; Metzdorff MT; Krause AH; Martin MA; Okies JE; Hill JG
    Ann Thorac Surg; 2000 Jan; 69(1):90-5. PubMed ID: 10654493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of abciximab on the outcome of emergency coronary artery bypass grafting after failed percutaneous coronary intervention.
    Singh M; Nuttall GA; Ballman KV; Mullany CJ; Berger PB; Holmes DR; Bell MR
    Mayo Clin Proc; 2001 Aug; 76(8):784-8. PubMed ID: 11499816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of coronary artery perforation in patients receiving abciximab.
    Del Campo C; Zelman R
    Catheter Cardiovasc Interv; 2001 Sep; 54(1):139-40. PubMed ID: 11553964
    [No Abstract]   [Full Text] [Related]  

  • 13. Bridge to operation with the GPIIb/IIIa inhibitor abciximab in high-risk coronary patients.
    Schoenhoff F; Kayhan N; Thomas G; Haase KK; Borggrefe M; Katus HA; Hagl S; Vahl CF
    Thorac Cardiovasc Surg; 2006 Apr; 54(3):150-6. PubMed ID: 16639674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 15. Surgical implications of platelet glycoprotein IIb-IIIa inhibition.
    Duke C; Grammie JS
    J Thorac Cardiovasc Surg; 1998 Dec; 116(6):1083-4. PubMed ID: 9832706
    [No Abstract]   [Full Text] [Related]  

  • 16. Abciximab and the risk of bleeding during emergency cardiac operations.
    Arjomand H; Mascarenhas DA; Morgan RJ
    Ann Thorac Surg; 1999 Jan; 67(1):292-3. PubMed ID: 10086586
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications.
    Boehrer JD; Kereiakes DJ; Navetta FI; Califf RM; Topol EJ
    Am J Cardiol; 1994 Dec; 74(11):1166-70. PubMed ID: 7977081
    [No Abstract]   [Full Text] [Related]  

  • 18. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
    Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
    Mukherjee D; Gurm H; Tang WH; Roffi M; Wolski K; Moliterno DJ; Guetta V; Ardissinio D; Bode C; Steg G; Lincoff AM; Topol EJ
    Am J Cardiol; 2002 Dec; 90(11):1198-203. PubMed ID: 12450598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk].
    Matos V; Marques AM; Oliveira H; Ramos D; Lopes P; Camacho M; Gonsalves A
    Rev Port Cardiol; 1998 Dec; 17(12):1001-5. PubMed ID: 9973861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.